header-bg6.jpg
 
Akili_Logo_simple.png
 

An entirely new class of medical products

 

Who We Are

At Akili, we're building clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. This new type of Electronic Medicine™ can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, and developed at a fraction of the cost of traditional medical approaches.

Akili was co-founded by PureTech, leading cognitive neuroscientists, and top-tier entertainment software creators. Our operational team is a mix of biomedical scientists and experts in medical device commercialization and interactive design

science3.png

Scientific Approach

Akili functions on the premise that advances in neuroscience research and consumer-facing technology are enabling a new way to sensitively measure neural function, and intervene in any measured deficits, wherever the patient may be.  Akili's products address both quantitative measurement of and intensive intervention in cognitive functions in a variety of patient populations.

The science behind our first platform, "Project: EVO", was developed at the University of California, San Francisco by Dr. Adam Gazzaley, Founding Director of the UCSF Neuroscience Imaging Center and Akili's Chief Science Advisor. Dr. Gazzaley's research has led to a patent-pending new software-based method to measure and improve a key system of executive function known as "interference processing." We've deployed these mechanics in a highly-engaging videogame-like environment that runs on mobile phones and tablets, and meets all requirements for rigorous clinical studies. The Project: EVO platform is currently being tested in a variety of clinical studies in multiple patient populations around the globe, including ADHD, autism, depression, and traumatic brain injury.

cog-background.png

Cognitive Engine

Our cutting-edge cognitive gaming engine enables 3 separate products for remote data-capture with extreme patient engagement.  Our proprietary adaptive mechanics allow the software to automatically personalize to the patient's ability level with no clinician input required. We're currently validating each product in a variety of specific patient populations.

 

Measure your population in a novel way

Traditional cognitive tests are barely tolerable by the patient and can lack sensitivity needed for subtle patient characterization.  Akili's one-time assessment achieves a proprietary baseline measurement of cognitive control in a format that engages the patient. Sensitive. High-quality data. Better patient experience.

Track cognitive status over time

Measurements over time allow for a plethora of uses, from tracking patients' conditions to understanding the effect of interventions on brain function.  Akili's proprietary cognitive control monitor allows for short measurements configurable to a custom tracking needs (hourly, daily, weekly, etc.).

Improve neural functioning & cognitive symptoms

Akili's flagship product, our proprietary multitasking cognitive trainer, provides a targeted way to potentially improve cognition and disease symptoms through at-home videogame play.  High-res data collection enables patient compliance tracking and progress analytics.

 
evo-phone.png

If you want to give your patients a brand new medical experience by running an innovative clinical trial with our software platform, Get in Touch!

partner-background.png

Partnerships

Akili works with top universities and premier partners in the healthcare space to bring our products to market.

Pfizer Pharmaceuticals Pfizer Pharmaceuticals (PFE) is currently funding a study to validate the ability of the Project:EVO platform to serve as a biomarker or cognitive endpoint for individuals at risk of developing Alzheimer's disease. This innovative study is the first in which a pharmaceutical company is using a video game to detect a major disease. The study will begin recruitment in 2014.

Pfizer Pharmaceuticals

Pfizer Pharmaceuticals (PFE) is currently funding a study to validate the ability of the Project:EVO platform to serve as a biomarker or cognitive endpoint for individuals at risk of developing Alzheimer's disease. This innovative study is the first in which a pharmaceutical company is using a video game to detect a major disease. The study will begin recruitment in 2014.

Shire Pharmaceuticals In 2013, Shire Pharmaceuticals' (SHPG) Strategic Investment group made a direct investment in Akili. Shire is a market-leader in ADHD medications, and has deep experience in ADHD clinical trials. In addition to the monetary investment, Akili and Shire have worked closely together to structure and launch Akili's first clinical study of Project:EVO in pediatric ADHD. The three-site study is currently underway.

Shire Pharmaceuticals

In 2013, Shire Pharmaceuticals' (SHPG) Strategic Investment group made a direct investment in Akili. Shire is a market-leader in ADHD medications, and has deep experience in ADHD clinical trials. In addition to the monetary investment, Akili and Shire have worked closely together to structure and launch Akili's first clinical study of Project:EVO in pediatric ADHD. The three-site study is currently underway.

National Institute of Mental health Akili is proud to be part of the first depression intervention study to be conducted entirely through smartphones and mobile tablets. Funded by the National Institutes of Mental Health, the study will explore feasibility of mobile recruitment, retention, and intervention strategies, and will include Akili's Project:EVO as one of the two randomized intervention arms. Recruitment will begin soon. See more at www.brightenstudy.com.

National Institute of Mental health

Akili is proud to be part of the first depression intervention study to be conducted entirely through smartphones and mobile tablets. Funded by the National Institutes of Mental Health, the study will explore feasibility of mobile recruitment, retention, and intervention strategies, and will include Akili's Project:EVO as one of the two randomized intervention arms. Recruitment will begin soon. See more at www.brightenstudy.com.

 

Additionally, Akili is in the process of licensing and accelerating product development of the very newest published and as-yet-unpublished neuroscience findings that could address major medical indications.

If you have a research program on a patient population with cognitive deficits, or new science that you would like to develop into engaging medical products, please contact Akili at info@akiliinteractive.com

newssection2.png

The Buzz

Akili's novel healthcare approach and the technology behind our first product platform has been covered extensively in recent popular and industry-specific media outlets. Stay tuned for more updates!

background.png

Our Team

Our team focuses on merging top science with great user experience. We believe patients deserve better, and we're working to make that a reality

 
"Why is 'tolerable' the user-experience goal of medicine?  If we make products fun for the patient, we get richer, higher-quality data with a superior experience" - Eddie

"Why is 'tolerable' the user-experience goal of medicine?  If we make products fun for the patient, we get richer, higher-quality data with a superior experience"

- Eddie

Eddie Martucci, PhD

COO

view bio

"By embracing, rather than fearing, scientific constraints, new and unique game designs can be discovered that would otherwise never have emerged." - MattO

"By embracing, rather than fearing, scientific constraints, new and unique game designs can be discovered that would otherwise never have emerged."

- MattO

Matthew Omernick

Executive Creative Director

view bio

"Running clinical studies is no different with a game than with a traditional device: attention to detail, planning, and the right outcomes make all the difference." - Scott

"Running clinical studies is no different with a game than with a traditional device: attention to detail, planning, and the right outcomes make all the difference."

- Scott

Scott C. Kellogg

VP of Operations

view bio

 
 
 
"It’s rewarding to blaze a trail that can make a difference.  The design, code, and all of us have traveled creative roads that we wouldn’t have otherwise traveled" - Piper

"It’s rewarding to blaze a trail that can make a difference.  The design, code, and all of us have traveled creative roads that we wouldn’t have otherwise traveled"

- Piper

Adam Piper

Lead Engineer / Designer

view bio

"Video games are data-harnessing machines.  Every frame, every movement tells us something about the user they can't even know about themselves" - Bower

"Video games are data-harnessing machines.  Every frame, every movement tells us something about the user they can't even know about themselves"

- Bower

Jeffery Bower, PhD

Dir. of Data Sci. & Psy.

view bio

 
 

Our Board and Co-Founding Advisors

 

 
Adam Gazzaley, MD PhD Chief Science Advisor view bio

Adam Gazzaley, MD PhD

Chief Science Advisor

view bio

Daphne Bavelier, PhD Co-Founding Advisor view bio

Daphne Bavelier, PhD

Co-Founding Advisor

view bio

Bennett Shapiro, MD Board Member view bio

Bennett Shapiro, MD

Board Member

view bio

Eric Elenko, PhD Board Member view bio

Eric Elenko, PhD

Board Member

view bio

 
 
Daphne Zohar Board Member view bio

Daphne Zohar

Board Member

view bio

Philip Rosedale Co-Founding Advisor view bio

Philip Rosedale

Co-Founding Advisor

view bio

Joi Ito Board Member view bio

Joi Ito

Board Member

view bio

Jamie Gates Board Member view bio

Jamie Gates

Board Member

view bio

 
white-graph2.png

 

Get In Touch!

Someone from the Akili team will get back to you shortly.